Free shipping on all orders over $ 500

Vesencumab

Cat. No. M24576
Vesencumab Structure
Synonym:

MNRP-1685A

Size Price Availability Quantity
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Vesencumab (MNRP-1685A) is IG1 antibody against neuropilin-1 (NRP-1). Vesencumab binds to NRP-1 and prevents the subsequent coupling of NRP-1 to VEGFR-2. Vesencumab has anti-angiogenic and anti-neoplastic activities. Vesencumab can be used in the research of metastatic solid tumors, including ovarian cancer.

Chemical Information
CAS Number 1205533-60-3
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yu Hin Tang, et al. Breast Cancer Res. Neuropilin-1 is over-expressed in claudin-low breast cancer and promotes tumor progression through acquisition of stem cell characteristics and RAS/MAPK pathway activation

[2] Amita Patnaik, et al. Cancer Chemother Pharmacol. A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid tumors

[3] Colin D Weekes, et al. Invest New Drugs. A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors

[4] Yan Xin, et al. Pharm Res. Anti-neuropilin-1 (MNRP1685A): unexpected pharmacokinetic differences across species, from preclinical models to humans

[5] Daniela Bumbaca, et al. Br J Pharmacol. Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice

Related Complement System Products
P014

P014 is a C5 antibody/CFH fragment fusion protein that can be used in studies related to paroxysmal sleep hemoglobinuria (PNH) and thrombotic microangiopathy (TMA).

POT-4

POT-4 (AL-78898A), a Compstatin derivative, is a potent inhibitor of complement factor C3 activation.

TLQP-21

TLQP-21, a VGF-derived peptide endowed of endocrine and extraendocrine properties, is a potent G-protein-coupled receptor complement-3a receptor 1 (C3aR1) agonist (EC50: mouse TLQP-21=10.3 μM; human TLQP-21=68.8 μM).

N-((Allyloxy)carbonyl)-N-methyl-L-alanine

N-((Allyloxy)carbonyl)-N-methyl-L-alanine is a Alanine derivative.

C5a Receptor agonist, mouse, human

C5a Receptor agonist, mouse, human is a biological active peptide.

  Catalog
Abmole Inhibitor Catalog




Keywords: Vesencumab, MNRP-1685A supplier, Complement System, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.